Pacific Biosciences of California, Inc. (PACB)

US — Healthcare Sector

Peers: NVTA TWST NTLA CRSP EDIT

Automate Your Wheel Strategy on PACB

With Tiblio's Option Bot, you can configure your own wheel strategy including PACB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol PACB
Rev/Share 0.5132
Book/Share 0.3087
PB 3.369
Debt/Equity 7.6291
CurrentRatio 6.6803
ROIC -0.9927

MktCap 312088400.0
FreeCF/Share -0.6169
PFCF -1.7042
PE -0.4694
Debt/Assets 0.8122
DivYield 0
ROE -1.704

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 5
P/B Score 2
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy

PACB
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

image for news All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy

PacBio Stock Slips Despite New China Distribution Deal With Haorui

PACB
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Neutral

PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide.

image for news PacBio Stock Slips Despite New China Distribution Deal With Haorui

PACB Stock May Rise Following the Deal With Chulalongkorn University

PACB
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive

PacBio and Chulalongkorn University launch Asia Pacific's first population-scale HiFi WGS newborn screening program, advancing precision medicine in Thailand.

image for news PACB Stock May Rise Following the Deal With Chulalongkorn University

PacBio Board Independent Investigation Concludes Allegations Unsubstantiated

PACB
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the “Special Committee”) has concluded its independent investigation into previously disclosed allegations from an attorney representing an employee impacted by our recent reduction in force regarding certain employment practices and cybersecurity matters of the Company. The allegations did not involve the current, or any previously reported, financial results, and the investigation found no improper employment practices and no material inaccuracies or omissions with respect to the cybersecurity disclosures in the Company's 2024 Form 10-K.

image for news PacBio Board Independent Investigation Concludes Allegations Unsubstantiated

PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates

PACB
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Negative

Despite strong Service and other revenues, PACB reports soft first-quarter 2025 results partly due to lower Revio system shipments.

image for news PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates

Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say

PACB
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

image for news Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say

First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand

PACB
Published: May 05, 2025 by: GlobeNewsWire
Sentiment: Neutral

Collaboration leverages HiFi's unique ability to reveal hidden variants, bringing a new level of precision to early life genetic screening Collaboration leverages HiFi's unique ability to reveal hidden variants, bringing a new level of precision to early life genetic screening

image for news First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand

PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million

PACB
Published: April 09, 2025 by: GlobeNewsWire
Sentiment: Neutral

Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025.

image for news PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million

Here's Why You Should Retain PacBio Stock in Your Portfolio Now

PACB
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive

PACB continues to deliver growth from its unique technologies amid macroeconomic concerns.

image for news Here's Why You Should Retain PacBio Stock in Your Portfolio Now

Scientists Solve One of Genomics' Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes

PACB
Published: March 17, 2025 by: GlobeNewsWire
Sentiment: Neutral

MENLO PARK, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a newly published study in Nature Communications unveiling a powerful new method for analyzing some of the most complex regions of the human genome. Led by researchers from PacBio, GeneDx, and a global consortium of genomics experts, the study utilizes Paraphase, an informatics tool that, when paired with HiFi long-read sequencing, allows for high-precision variant detection and copy number analysis in 316 previously inaccessible segmental duplication regions, including 9 challenging medically-relevant genes.

image for news Scientists Solve One of Genomics' Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes

Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock

PACB
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Negative

Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock

Pacific Biosciences of California, Inc. (PACB) Q4 2024 Earnings Call Transcript

PACB
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance and Investor Relations Christian Henry - President and CEO Michele Farmer - Chief Accounting Officer Conference Call Participants Tycho Peterson - Jefferies Kyle Mikson - Canaccord Dan Brennan - TD Cowen Doug Schenkel - Wolfe Research Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Subbu Nambi - Guggenheim Sung Ji Nam - Scotia Bank Mason Carrico - Stephens Operator Good day. And welcome to the PacBio Fourth Quarter 2024 Earnings Conference Call.

image for news Pacific Biosciences of California, Inc. (PACB) Q4 2024 Earnings Call Transcript

Compared to Estimates, Pacific Biosciences (PACB) Q4 Earnings: A Look at Key Metrics

PACB
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

image for news Compared to Estimates, Pacific Biosciences (PACB) Q4 Earnings: A Look at Key Metrics

About Pacific Biosciences of California, Inc. (PACB)

IPO Date 2010-10-27
Website https://www.pacb.com
Industry Medical - Devices
CEO Mr. Christian O. Henry M.B.A.
Employees 575

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.